华大智造发布2025年度业绩快报，亏损2.369亿元

Core Viewpoint - The company Huada Zhi Zao is set to release its 2025 annual report, indicating a net profit loss of 236.9 million yuan, a year-on-year decrease of 60.57% [1]. Financial Performance - For the reporting period, the company achieved an operating revenue of 2.779 billion yuan, a decrease of 7.73% year-on-year [2]. - The net profit attributable to the parent company was -236.9 million yuan, with a year-on-year loss reduction of 60.57% [2]. - The net profit attributable to the parent company, excluding non-recurring gains and losses, was -377.8 million yuan, with a year-on-year loss reduction of 42.11% [2]. - As of the end of the reporting period, total assets amounted to 10.24 billion yuan, a decrease of 0.73% year-on-year [2]. - The equity attributable to the parent company was 7.63 billion yuan, a decrease of 3.27% year-on-year [2]. Factors Affecting Performance - The decline in operating revenue and gross profit contribution was primarily due to intensified market competition, leading to a drop in sales prices of certain products, and a shift in product sales structure with an increased proportion of low-throughput gene sequencing products [3]. - Sales, management, and R&D expenses collectively decreased by approximately 19% year-on-year due to the implementation of measures aimed at improving quality and efficiency [3]. - Fluctuations in foreign currency exchange rates resulted in increased foreign exchange gains from monetary items held in foreign currencies [4]. - The company reversed tax provisions related to uncertainties from previous years, leading to a decrease in income tax expenses [4]. Significant Changes in Financial Metrics - The operating profit, total profit, and net profit attributable to the parent company, excluding non-recurring gains and losses, saw a reduction in losses of 47.55%, 46.41%, and 42.11% respectively [5]. - The decrease in gross profit contribution was approximately 200 million yuan due to market competition and changes in product sales structure [5]. - The company’s measures to enhance quality and efficiency contributed to a significant reduction in expenses [5]. - The net profit attributable to the parent company showed a year-on-year loss reduction of 60.57%, with basic earnings per share reflecting a 60.27% decrease in losses compared to the previous year [6]. Company Overview - Huada Zhi Zao specializes in the research, development, production, and sales of gene sequencing instruments, laboratory automation equipment, and related consumables in the life sciences and biotechnology sectors [6]. - In the last 90 days, six institutions provided ratings for the stock, with four buy ratings and two hold ratings, and the average target price set at 91.0 yuan [6].